Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Blood (2024) 143 (2): 178–182.

https://doi.org/10.1182/blood.2023022345

Published: 2024

Includes: Supplemental data

Journal Articles

Polygenic Germline Risk of Common Haematological Traits Drives Clonal Selection on JAK2 V617F and Development of Myeloproliferative Neoplasms

Jyoti Nangalia, Jing Guo, Klaudia Walter, Pedro Quiros, Muxin Gu, E Joanna Baxter, John Danesh, Emanuele Di Angelantonio, David Roberts, Paola Guglielmelli, Claire N Harrison, Anna L Godfrey, Anthony R Green, George Vassiliou, Dragana Vuckovic, Nicole Soranzo

Blood (2023) 142 (Supplement 1): 863.

https://doi.org/10.1182/blood-2023-189551

Published: 2023

Journal Articles

Essential thrombocythemia: challenges in clinical practice and future prospects

Anna L. Godfrey, Anna C. Green, Claire N. Harrison

Blood (2023) 141 (16): 1943–1953.

https://doi.org/10.1182/blood.2022017625

Published: 2023

Journal Articles

Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Blood (2022) 140 (Supplement 1): 1781–1783.

https://doi.org/10.1182/blood-2022-157273

Published: 2022

Journal Articles

Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib

Blood (2022) 140 (Supplement 1): 9721–9723.

https://doi.org/10.1182/blood-2022-162417

Published: 2022

Journal Articles

Clonal hematopoiesis is not significantly associated with COVID-19 disease severity

Blood (2022) 140 (14): 1650–1655.

https://doi.org/10.1182/blood.2022015721

Published: 2022

Includes: Supplemental data

Journal Articles

Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Chandan Saha, Carolyn Mead-Harvey, Adam J. Mead, Rebecca H. Boucher, Sonia Fox, Isaak Ailts, Christina Yap, Aimee E Jackson, Joanne Ewing, Jason Coppell, Steve Knapper, Mark W. Drummond, Anna L Godfrey, Amylou C. Dueck, Ruben A. Mesa, Robyn Scherber, Mary Frances McMullin, Holly L. Geyer, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2021-151568

Published: 2021

Journal Articles

Changes in Clonal Architecture Inform MPN Disease Course in Advance of Phenotypic Manifestations

Joe S Lee, Nicholas Williams, Joanna E Baxter, Anna L Godfrey, Kate Milne, Karim Mane, David C Wedge, Peter J. Campbell, Anthony R Green, Jyoti Nangalia

Blood (2021) 138 (Supplement 1): 3590.

https://doi.org/10.1182/blood-2021-152436

Published: 2021

Journal Articles

Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera

Isaak Ailts, Carolyn Mead-Harvey, Adam J. Mead, Sonia Fox, Rebecca H. Boucher, Christina Yap, Chandan Saha, Robyn Scherber, Aimee Jackson, Joanne Ewing, Jason Coppell, Steve Knapper, Mark W. Drummond, Anna L Godfrey, Amylou C. Dueck, Mary Frances McMullin, Ruben A. Mesa, Claire N. Harrison, Holly L. Geyer

Blood (2021) 138 (Supplement 1): 3644.

https://doi.org/10.1182/blood-2021-147637

Published: 2021

Journal Articles

Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment

Tim H. H. Coorens, Grace Collord, Wanhua Lu, Emily Mitchell, Jannat Ijaz, Thomas Roberts, Thomas R. W. Oliver, G. A. Amos Burke, Michael Gattens, Emmy Dickens, Jyoti Nangalia, Marc Tischkowitz, John Anderson, Adam Shlien, Anna L. Godfrey, Matthew J. Murray, Sam Behjati

Blood (2021) 137 (21): 2992–2997.

https://doi.org/10.1182/blood.2020010150

Published: 2021

Includes: Supplemental data

Journal Articles

Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms

Nicholas Williams, PhD, Joe Lee, MBBS, Luiza Moore, PhD, Joanna E Baxter, PhD, James Hewinson, PhD, Kevin J Dawson, PhD, Andrew Menzies, MSc, Anna L Godfrey, PhD, Anthony R Green, PhDFRCPath FMedSci, Peter J Campbell, PhD, Jyoti Nangalia, MBBChir

Blood (2020) 136 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2020-143813

Published: 2020

Journal Articles

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Claire Harrison, DM, FRCP, FRCPath, Joanna Baxter, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Thomas McKerrell, MD PhD, Aimee Jackson, BSc, MSc, Rachel S Fletcher, PhD, Adam J. Mead, MD PhD, Steve Knapper, BMBCh, MRCP, FRCPath, DM, Joanne Ewing, MD PhD, Nauman M Butt, MD, Manish Jain, MBBS, MRCP, FRCpath, Sebastian Francis, MBChB, FRCPath, MD, Fiona J Clark, FRCP, FRCPath, Jason Coppell, MBBS, Mary Frances McMullin, MDFRCP, FRCPath, Frances Wadelin, MB ChB, PhD FRCPath, Srinivasan Narayanan, FRCP, FRCPath, Dragana Milojkovic, Mark W. Drummond, PhD FRCPath, Mallika Sekhar, MBBS, MD, Maike Paramor, James Roberts, BSc, Rachel Glover, BSc, Erica Harris, MSc, Luigi Grassi, PhD, Alba Rodriguez-Meira, PhD, Jason Carroll, PhD FMedSci, José-Ezequiel Martín, PhD, Giuditta Corbizi Fattori, PhD, Zijian Fang, BSc, Anna L Godfrey, BMBCh, PhD, Simón Méndez-Ferrer, PhD

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-134764

Published: 2020

Journal Articles

Niche Heterogeneity Impacts Evolution of Myeloproliferative Neoplasms Driven By the Same Oncogenic Pathway

Blood (2018) 132 (Supplement 1): 98.

https://doi.org/10.1182/blood-2018-99-113495

Published: 2018

Journal Articles

Hydroxycarbamide Plus Aspirin Vs Aspirin Alone in Intermediate Risk Essential Thrombocythemia: Results of the PT-1 International, Prospective, Randomized Clinical Trial

Anna L. Godfrey, BMBCh, PhD MRCP, FRCPath, Peter J Campbell, MD PhD, Cathy MacLean, BSc, MSc, MBA, Georgina Buck, BSc, MSc, Clare L. East, BSc, Julia Cook, BSc, Julie Temple, BSc, Bridget S. Wilkins, MD FRCPath, Keith Wheatley, DPhil, Jyoti Nangalia, MBBChir, MA, MRCP, FRCPath, PhD, Jacob Grinfeld, MBChB, BSc, MRCP, FRCPath, Mary Frances Frances McMullin, MB,Bch BAO, MD FRCPath, Cecily Forsyth, MB BS, Jean-Jacques Kiladjian, MD PhD, Anthony R. Green, FRCP, FRCPath, FMed Sci, Claire N. Harrison, BMBCh, DM, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 319.

https://doi.org/10.1182/blood.V130.Suppl_1.319.319

Published: 2017

Journal Articles

Personalized Prognostic Predictions for Patients with Myeloproliferative Neoplasms through Integration of Comprehensive Genomic and Clinical Information

Blood (2017) 130 (Supplement 1): 491.

https://doi.org/10.1182/blood.V130.Suppl_1.491.491

Published: 2017

Journal Articles

Nongenetic stochastic expansion of JAK2V617F -homozygous subclones in polycythemia vera?

Anna L. Godfrey, Jyoti Nangalia, E. Joanna Baxter, Charles E. Massie, David G. Kent, Elli Papaemmanuil, Peter J. Campbell, Anthony R. Green

Blood (2014) 124 (22): 3332–3334.

https://doi.org/10.1182/blood-2014-09-603043

Published: 2014

Includes: Supplemental data

Journal Articles

JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease

Juan Li, David G. Kent, Anna L. Godfrey, Harriet Manning, Jyoti Nangalia, Athar Aziz, Edwin Chen, Kourosh Saeb-Parsy, Juergen Fink, Rachel Sneade, Tina L. Hamilton, Dean C. Pask, Yvonne Silber, Xiaodong Zhao, Cedric Ghevaert, Pentao Liu, Anthony R. Green

Blood (2014) 123 (20): 3139–3151.

https://doi.org/10.1182/blood-2013-06-510222

Published: 2014

Includes: Supplemental data

Journal Articles

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

Jyoti Nangalia, MBBChir FRCPath, Charles Massie, PhD, E Joanna Baxter, PhD, Francesca L Nice, MRes, Gunes Gundem, PhD, David Wedge, PhD, Edward Avezov, PhD, Juan Li, PhD, Karoline Kollmann, PhD, David G. Kent, PhD, Athar Aziz, PhD, Anna L Godfrey, BMBCh FRCPath, Jonathan Hinton, MSc, Inigo Martincorena, PhD, Peter Van Loo, PhD, Amy V Jones, PhD, Paola Guglielmelli, PhD MD, Patrick Tarpey, PhD, Heather P Harding, PhD, John D Fitzpatrick, BA, Calum T Goudie, BA, Christina A Ortmann, MD, Stephen J Loughran, PhD, Keiran Raine, MSc, David Jones, MSc, Adam Butler, MSc, Jon W Teague, MSc, Sarah O'Meara, Stuart McLaren, Michele Bianchi, Yvonne Silber, MSc, Danai Dimitropolou, BSc, David Bloxham, MSc FRCPath, Laura J Mudie, BSc, Mark Maddison, BSc, Ben Robinson, BSc, Clodagh Keohane, MD, Cathy MacLean, MSc, Kate Hill, BM BS, Kim H. Orchard, MBBS, PhD, FRCP, FRCPath, Sudhir Tauro, PhD, Ming-Qing Du, MB, PhD, Mel Greaves, PhD, FRS, David Bowen, MD, PhD, Brian Huntly, MBChB FRCPath PhD, Claire N Harrison, DM, FRCP, FRCPath, Nicholas C.P. Cross, PhD, FRCPath, David Ron, MD, Alessandro M Vannucchi, MD, Elli Papaemmanuil, PhD, Peter J. Campbell, PhD, Anthony R Green, FRCPath FMedSci

Blood (2013) 122 (21): LBA-2.

https://doi.org/10.1182/blood.V122.21.LBA-2.LBA-2

Published: 2013

Journal Articles

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone

Anna L. Godfrey, Edwin Chen, Francesca Pagano, Christina A. Ortmann, Yvonne Silber, Beatriz Bellosillo, Paola Guglielmelli, Claire N. Harrison, John T. Reilly, Frank Stegelmann, Fontanet Bijou, Eric Lippert, Mary F. McMullin, Jean-Michel Boiron, Konstanze Döhner, Alessandro M. Vannucchi, Carlos Besses, Peter J. Campbell, Anthony R. Green

Blood (2012) 120 (13): 2704–2707.

https://doi.org/10.1182/blood-2012-05-431791

Published: 2012

Includes: Supplemental data

Journal Articles

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Blood (2011) 118 (24): 6239–6246.

https://doi.org/10.1182/blood-2011-09-377275

Published: 2011

Includes: Supplemental data

NARROW

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Polygenic Germline Risk of Common Haematological Traits Drives Clonal Selection on JAK2 V617F and Development of Myeloproliferative Neoplasms

Essential thrombocythemia: challenges in clinical practice and future prospects

Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib

Clonal hematopoiesis is not significantly associated with COVID-19 disease severity

Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Changes in Clonal Architecture Inform MPN Disease Course in Advance of Phenotypic Manifestations

Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera

Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment

Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Niche Heterogeneity Impacts Evolution of Myeloproliferative Neoplasms Driven By the Same Oncogenic Pathway

Hydroxycarbamide Plus Aspirin Vs Aspirin Alone in Intermediate Risk Essential Thrombocythemia: Results of the PT-1 International, Prospective, Randomized Clinical Trial

Personalized Prognostic Predictions for Patients with Myeloproliferative Neoplasms through Integration of Comprehensive Genomic and Clinical Information

Nongenetic stochastic expansion of JAK2V617F -homozygous subclones in polycythemia vera?

JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only